dsp 4 has been researched along with Parkinsonian Disorders in 5 studies
DSP 4: RN given refers to parent cpd
Parkinsonian Disorders: A group of disorders which feature impaired motor control characterized by bradykinesia, MUSCLE RIGIDITY; TREMOR; and postural instability. Parkinsonian diseases are generally divided into primary parkinsonism (see PARKINSON DISEASE), secondary parkinsonism (see PARKINSON DISEASE, SECONDARY) and inherited forms. These conditions are associated with dysfunction of dopaminergic or closely related motor integration neuronal pathways in the BASAL GANGLIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Using the rat model of parkinsonism with an additional noradrenergic degeneration induced by the N-(-2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) toxin we evaluated whether the circling motor activity and dose-failure episodes induced by levodopa (L-DOPA) differ between single (6-OHDA) and double (6-OHDA + DSP-4) denervated animals challenged with a single daily dose of L-DOPA." | 1.35 | Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats. ( Barbanoj, M; Gich, I; Kulisevsky, J; Pérez, V; Rodríguez-Alvarez, J; Rubio, A; Sosti, V, 2009) |
| "Behaviour was evaluated by catalepsy tests and activity box." | 1.32 | Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats. ( Schmidt, WJ; Srinivasan, J, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (80.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Faggiani, E | 1 |
| Delaville, C | 1 |
| Benazzouz, A | 1 |
| Pérez, V | 1 |
| Sosti, V | 1 |
| Rubio, A | 1 |
| Barbanoj, M | 1 |
| Gich, I | 1 |
| Rodríguez-Alvarez, J | 1 |
| Kulisevsky, J | 1 |
| Srinivasan, J | 2 |
| Schmidt, WJ | 2 |
| Thomas, B | 1 |
| von Coelln, R | 1 |
| Mandir, AS | 1 |
| Trinkaus, DB | 1 |
| Farah, MH | 1 |
| Leong Lim, K | 1 |
| Calingasan, NY | 1 |
| Flint Beal, M | 1 |
| Dawson, VL | 1 |
| Dawson, TM | 1 |
5 other studies available for dsp 4 and Parkinsonian Disorders
| Article | Year |
|---|---|
The combined depletion of monoamines alters the effectiveness of subthalamic deep brain stimulation.
Topics: Animals; Anxiety Disorders; Benzylamines; Biogenic Monoamines; Catalepsy; Corpus Striatum; Deep Brai | 2015 |
Noradrenergic modulation of the motor response induced by long-term levodopa administration in Parkinsonian rats.
Topics: Animals; Antiparkinson Agents; Benzylamines; Brain; Disease Models, Animal; Dopamine; Dose-Response | 2009 |
Potentiation of parkinsonian symptoms by depletion of locus coeruleus noradrenaline in 6-hydroxydopamine-induced partial degeneration of substantia nigra in rats.
Topics: 3,4-Dihydroxyphenylacetic Acid; Adrenergic Agents; Animals; Behavior, Animal; Benzylamines; Cataleps | 2003 |
Functional recovery of locus coeruleus noradrenergic neurons after DSP-4 lesion: effects on dopamine levels and neuroleptic induced-parkinsonian symptoms in rats.
Topics: Animals; Antipsychotic Agents; Benzylamines; Dopamine; Locus Coeruleus; Male; Motor Activity; Neuron | 2004 |
MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Benzylamines; Catecholamines; Cell Survival; | 2007 |